Brief: Affimed, MD Anderson to collaborate on clinical immuno-oncology development
04/01/2017 10:00
Jan 4 (Reuters) - Affimed NV AFMD.O :
* Affimed and MD Anderson announce clinical immuno-oncology
development collaboration
* Collaboration to evaluate Affimed's tandab technology in
combination with MD Anderson's natural killer cell product
Source text for Eikon: ID:nGNXNNSXBa
Further company coverage: AFMD.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Affimed NV
See all newsBrief: Affimed Announces Receipt Of Nasdaq Delisting Notice
Brief: Affimed Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Affimed Reports Positive Clinical Update On Afm24/Atezolizumab Combination Therapy
Brief: Affimed NV Files For Common Stock Offering Of Up To $20 Million - SEC Filing
Brief: Affimed NV Files For Mixed Shelf Offering Of Up To $20 Million